Investors searching for ASX growth shares often look for the same ingredients: market leadership, a strong competitive moat, and a share price that doesn’t fully reflect future potential.
Telix Pharmaceuticals Ltd (ASX: TLX) and Catapult Sports Ltd (ASX: CAT) fit that description.
Both companies have faced significant share price pressure over the past year. Telix shares are up 26% year to date but remain down 43% over 12 months. Catapult has fared even worse, falling 28% in 2026 and 47% over the past year.
Despite those declines, analysts see substantial upside ahead for the ASX shares. Here’s why.
Telix Pharmaceuticals
Telix develops radiopharmaceutical products used to diagnose and treat cancer. Its flagship products target some of the largest oncology markets globally, giving the company exposure to a rapidly growing area of healthcare.
One of Telix’s biggest strengths is its moat. Developing radiopharmaceuticals requires specialised expertise, manufacturing capabilities, regulatory approvals, and distribution networks that are difficult and expensive to replicate. Those barriers help protect established players such as Telix.
After a difficult period, the ASX growth share appears to have found its groove since February. The rebound began when the company confirmed it had filed for a key regulatory approval in Europe.
Momentum continued into April. Telix announced that the US Food and Drug Administration had accepted its New Drug Application for TLX101-Px (Pixclara®), an important milestone for the business. It also revealed a major collaboration with US biotechnology giant Regeneron Pharmaceuticals, further strengthening confidence in its long-term prospects.
Analysts remain highly optimistic. TradingView data shows the majority of brokers rate the $5 billion ASX growth share as a strong buy. The most bullish price target sits at $31.64 per share, implying upside of approximately 123% from current levels.
Morgans is also positive on the stock, with a $24.33 price target, which suggests a 71% upside. The broker recently noted that increasing consolidation across the healthcare sector could generate additional interest in Telix shares.
Catapult Sports
Catapult develops athlete performance and analytics technology used by professional sporting teams around the world.
Its solutions help coaches and performance staff monitor player workloads, reduce injury risks, analyse performance, and improve decision-making. The technology is widely used across major sporting organisations, including teams in the AFL, NRL, Premier League, NFL, NBA, MLB, and international rugby competitions.
That extensive customer base gives Catapult a significant competitive advantage. Once teams integrate the company’s hardware, software, and performance data into their operations, switching providers becomes difficult. This creates sticky customer relationships and recurring revenue streams.
Despite these strengths, investors have remained cautious, helping drive the share price of the ASX growth share sharply lower over the past year.
Analysts, however, remain overwhelmingly bullish. TradingView data shows every analyst covering Catapult currently rates it as either a buy or strong buy. The average price target stands at $5.72, implying upside of approximately 94% from current levels. The most optimistic forecast suggests the ASX growth stock could rise by as much as 175% over the next year.
Morgans has a buy rating and a $5.40 target price. Based on the current share price of $2.95, that points to potential gains of roughly 83%.
The post 2 ASX growth shares that could double your money appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Here are the 10 most shorted ASX shares
- Healthcare shares led the ASX 200 last week. Is a sector comeback underway?
- Why these 2 battered ASX tech shares look ready to surge
- 3 top ASX 300 shares tipped to jump 30% to 50%
- 3 incredible ASX growth shares tipped to rise 20% to 70%
Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended Catapult Sports. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.